FDA Clearance Tracker · K163274
AggreGuide A-100 AA Assay, AggreGuide A-100 Instrument
Last checked: Nov 20, 2026Latest source record: Apr 5, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Apr 5, 2017
Substantially Equivalent
Time to decision
135 days
Received Nov 21, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K163274
- Device name
- AggreGuide A-100 AA Assay, AggreGuide A-100 Instrument
- Applicant
- Aggredyne, Inc.
- Applicant location
- Houston, TX
- Received
- Nov 21, 2016
- Decided
- Apr 5, 2017
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- System, Automated Platelet Aggregation (JOZ)
- Device class
- Class II
- Regulation
- 21 CFR 864.5700
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code JOZ. The earliest in FDA's data is K760893, decided Jan 12, 1977.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K163274
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Aggredyne, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- AggreGuide A-100 ADP510(k)
K181777 · Decided Mar 29, 2019 · 269 days after receipt
Device type: System, Automated Platelet Aggregation (JOZ) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.